

Session 2: Veterinary vaccines: proposal to facilitate licensing in general

Revision of Annex 1, Title II and IV

- ❖ Distinguish:
 - regular licensing reflecting major vs minor markets (MUMS)
 - emergency vaccination (exceptional circumstances)
- Benefit Risk Assessment instead of no risk policy**
- ❖ Early input/dialog with Authorities
- ❖ Coordinated cooperation with NRAs, OMCLs and GMP-inspectors
- ❖ Obligatory centrally approved **Master Files** (cells, platforms, antigens) will accelerate scientific assessment
- ❖ Definition GMO to update to the variety of novel technologies
- ❖ Shorten administrative procedure pre- and post scientific assessment to accelerate placing on the market
- ❖ 3Rs: facilitate introduction of non-animal tests for final batch control
 - better characterisation of final products
 - introduction of **consistency approach**

Ready for further discussion and active contributions:

General: iabs.org

Platforms: zapi-imi.eu Final Meeting, Leuven or Hannover, January 2020

3Rs and consistency: vac2vac.eu 3R Meeting (IABS and VAC2VAC), Bangkok, December 2019,
Training of assessors when required

Contact: Carmen.Jungbaeck@iabs.org

